Bio-Techne ESR1 Mutation Assay

Bio-Techne subsidiary Asuragen has launched its research-use-only ESR1 mutation monitoring assay consisting of the QuantideX qPCR ESR1 exoMutation Kit paired with the ExoLution Plus cfDNA + exoRNA Isolation Kit. ESR1 mutations are linked to hormone receptor-positive (HR+) metastatic breast cancer, often emerging after treatment has begun, and detecting them quickly can help clinicians spot the early warning signs of treatment resistance and adjust therapies as needed. The Asuragen assay was designed to detect 11 ESR1 ligand-binding domain mutations in samples at very high sensitivity by detecting the molecular signal from both cell-free DNA and exosomal RNA. The test can be used with existing qPCR technology.